Lonza forecasts $7.9B in annual revenues by 2022, helped by Capsugel buy

Lonza forecasts $7.9B in annual revenues by 2022.

Swiss CDMO Lonza forecast in its half-year earnings report it will produce about $7.9 billion in annual revenues by 2022, strengthened by the recent purchase of Capsugel.

The company also noted its new Visp-based Ibex manufacturing service as an additional boost to the earnings forecast.

The blockbuster $5.5 billion deal for Capsugel, a U.S.-based contract capsule and drug producers, was announced late last year and closed in the second quarter of this year. Lonza bought Capsugel from KKR. The deal included refinancing $2 billion in Capsugel debt.

At the time, Lonza said the purchase would be accretive from the start and eventually provide about $100 million in savings through cross-selling opportunities and by combining manufacturing and services.

“Lonza’s continued growth shows the company’s strength and ability to shape the future along the healthcare continuum with our customer-oriented market approach, ongoing operational excellence and new innovative offerings,” Richard Ridinger, Lonza’s CEO, said in a statement. “The outstanding results in the first half 2017 are fully consistent with our outlook for the full year.”

For the first half of 2017, the company reported a 15% increase in revenues to $2.4 million while operating earnings grew 43.3% to $470 million. The company’s pharmaceutical and biotech segment jumped 27% to $1.12B versus the same period last year, and the unit recorded operating earnings—core EBIT—that soared 71.7% to $287.1 million.


Suggested Articles

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.

It took four tries over four years, but Perrigo has finally gotten FDA approval of its generic of Teva’s tricky-to-make ProAir HFA asthma inhaler.